276 related articles for article (PubMed ID: 37371986)
1. Rational Design of Multifunctional Ferulic Acid Derivatives Aimed for Alzheimer's and Parkinson's Diseases.
Guzmán-López EG; Reina M; Hernández-Ayala LF; Galano A
Antioxidants (Basel); 2023 Jun; 12(6):. PubMed ID: 37371986
[TBL] [Abstract][Full Text] [Related]
2. Chalcone Derivatives with a High Potential as Multifunctional Antioxidant Neuroprotectors.
Pérez-González A; Castañeda-Arriaga R; Guzmán-López EG; Hernández-Ayala LF; Galano A
ACS Omega; 2022 Nov; 7(43):38254-38268. PubMed ID: 36340167
[TBL] [Abstract][Full Text] [Related]
3. Quinoline Derivatives: Promising Antioxidants with Neuroprotective Potential.
Hernández-Ayala LF; Guzmán-López EG; Galano A
Antioxidants (Basel); 2023 Oct; 12(10):. PubMed ID: 37891932
[TBL] [Abstract][Full Text] [Related]
4. CADMA-Chem: A Computational Protocol Based on Chemical Properties Aimed to Design Multifunctional Antioxidants.
Guzman-Lopez EG; Reina M; Perez-Gonzalez A; Francisco-Marquez M; Hernandez-Ayala LF; Castañeda-Arriaga R; Galano A
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362034
[TBL] [Abstract][Full Text] [Related]
5. Computationally Designed Sesamol Derivatives Proposed as Potent Antioxidants.
Castro-González LM; Alvarez-Idaboy JR; Galano A
ACS Omega; 2020 Apr; 5(16):9566-9575. PubMed ID: 32363309
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Sang Z; Pan W; Wang K; Ma Q; Yu L; Yang Y; Bai P; Leng C; Xu Q; Li X; Tan Z; Liu W
Eur J Med Chem; 2017 Apr; 130():379-392. PubMed ID: 28279845
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective Properties of Ferulic Acid in Preclinical Models of Alzheimer's Disease: A Systematic Literature Review.
Zhou S; Dong X
Curr Med Chem; 2023; 30(24):2796-2811. PubMed ID: 36065925
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.
Hitge R; Smit S; Petzer A; Petzer JP
Bioorg Med Chem Lett; 2020 Jun; 30(12):127188. PubMed ID: 32299731
[TBL] [Abstract][Full Text] [Related]
9. Boosting caffeic acid performance as antioxidant and monoamine oxidase B/catechol-O-methyltransferase inhibitor.
Chavarria D; Benfeito S; Soares P; Lima C; Garrido J; Serrão P; Soares-da-Silva P; Remião F; Oliveira PJ; Borges F
Eur J Med Chem; 2022 Dec; 243():114740. PubMed ID: 36116233
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer's disease.
Patel CN; Georrge JJ; Modi KM; Narechania MB; Patel DP; Gonzalez FJ; Pandya HA
J Biomol Struct Dyn; 2018 Nov; 36(15):3938-3957. PubMed ID: 29281938
[TBL] [Abstract][Full Text] [Related]
11. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
12. Rational Design and Multibiological Profiling of Novel Donepezil-Trolox Hybrids against Alzheimer's Disease, with Cholinergic, Antioxidant, Neuroprotective, and Cognition Enhancing Properties.
Cai P; Fang SQ; Yang XL; Wu JJ; Liu QH; Hong H; Wang XB; Kong LY
ACS Chem Neurosci; 2017 Nov; 8(11):2496-2511. PubMed ID: 28806057
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Potential of Ferulic Acid in Alzheimer's Disease.
Turkez H; Arslan ME; Barboza JN; Kahraman CY; de Sousa DP; Mardinoğlu A
Curr Drug Deliv; 2022; 19(8):860-873. PubMed ID: 34963433
[TBL] [Abstract][Full Text] [Related]
14. Further SAR studies on natural template based neuroprotective molecules for the treatment of Alzheimer's disease.
Singh YP; Shankar G; Jahan S; Singh G; Kumar N; Barik A; Upadhyay P; Singh L; Kamble K; Singh GK; Tiwari S; Garg P; Gupta S; Modi G
Bioorg Med Chem; 2021 Sep; 46():116385. PubMed ID: 34481338
[TBL] [Abstract][Full Text] [Related]
15. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
de Beer AD; Legoabe LJ; Petzer A; Petzer JP
Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel naturally-inspired multifunctional molecules for the management of Alzheimer's disease.
Singh YP; Tej GNVC; Pandey A; Priya K; Pandey P; Shankar G; Nayak PK; Rai G; Chittiboyina AG; Doerksen RJ; Vishwakarma S; Modi G
Eur J Med Chem; 2020 Jul; 198():112257. PubMed ID: 32375073
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2019; 19(2):133-145. PubMed ID: 31258092
[TBL] [Abstract][Full Text] [Related]
18. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
[TBL] [Abstract][Full Text] [Related]
19. Prospecting for new catechol-
da Silva IR; Parise MR; Pereira M; da Silva RA
J Biomol Struct Dyn; 2021 Oct; 39(16):5872-5891. PubMed ID: 32691671
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation.
Anastassova N; Aluani D; Kostadinov A; Rangelov M; Todorova N; Hristova-Avakumova N; Argirova M; Lumov N; Kondeva-Burdina M; Tzankova V; Yancheva D
Neural Regen Res; 2021 Nov; 16(11):2299-2309. PubMed ID: 33818516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
